ZACHARY REESE: Open Payments
NPI 1285395194 · OREM, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,179 in 64 payments from 22 companies in 2025. Trend: 2023 $1,069 · 2024 $1,250 · 2025 $1,179
Food & beverage: $1,179
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $319 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| Lilly USA, LLC | 5 | $83 |
| Viatris Specialty LLC | 3 | $81 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $72 |
| GlaxoSmithKline, LLC. | 4 | $63 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $53 |
| Amgen Inc. | 3 | $50 |
| Novo Nordisk Inc | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
Products named: VRAYLAR, REXULTI, QULIPTA, YUPELRI, UBRELVY, JARDIANCE, Kerendia, EVENITY.
Industry payments across UT — which companies pay providers there.
